comparemela.com

Latest Breaking News On - Jack anders - Page 7 : comparemela.com

Victory Capital Management Inc Decreases Stock Position in Revolution Medicines, Inc (NASDAQ:RVMD)

Victory Capital Management Inc. trimmed its position in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 5.9% in the 1st quarter, HoldingsChannel reports. The firm owned 45,410 shares of the company’s stock after selling 2,860 shares during the quarter. Victory Capital Management Inc.’s holdings in Revolution Medicines were worth $984,000 as of its most recent […]

Revolution Medicines (RVMD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $32.00 price objective on the stock. HC Wainwright also issued estimates for Revolution Medicines’ Q2 2023 earnings at ($0.81) EPS, Q3 2023 earnings at ($0.91) EPS, […]

Revolution Medicines (NASDAQ:RVMD) Given New $35 00 Price Target at Needham & Company LLC

Revolution Medicines (NASDAQ:RVMD – Free Report) had its price target increased by Needham & Company LLC from $31.00 to $35.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. They currently have a buy rating on the stock. A number of other research analysts have also recently commented on the company. JPMorgan Chase […]

Revolution Medicines (NASDAQ:RVMD) Given New $40 00 Price Target at Oppenheimer

Revolution Medicines (NASDAQ:RVMD – Free Report) had its price objective upped by Oppenheimer from $35.00 to $40.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. Oppenheimer currently has an outperform rating on the stock. Several other equities analysts also recently issued reports on RVMD. HC Wainwright reissued a buy rating and set […]

Revolution Medicines (NASDAQ:RVMD) Rating Reiterated by HC Wainwright

Revolution Medicines (NASDAQ:RVMD – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $32.00 price target on the stock. HC Wainwright’s price objective would suggest a potential downside of 2.38% from the […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.